News

APEIRON pact for new checkpoint inhibitor with IMBA and MedUni Wien

Vienna, Austria

APEIRON Biologics AG, a company focused on cancer immunotherapy has announced the signing of an agreement with the Institute of Molecular Biotechnology GmbH (IMBA) of the Austrian Academy of Sciences and the Medical University of Vienna (MedUni Wien).

NBHA joins hands with 70 organizations globally to support fragility fracture network's call to action

Arlington

The statistics on osteoporosis-related bone breaks are alarming and will only get worse as the Baby Boomer population continues aging.

Broad Institute of MIT, Bayer partner to usher in innovative technologies to address heart failure and pursue new drug targets

Cambridge, Mass

The Broad Institute of MIT and Harvard and Bayer are launching the Precision Cardiology Laboratory (PCL), a new endeavor that will pursue scientific insights aimed at developing new therapies for heart failure.

US FDA to collaborate with internet stakeholders to stop illegal online sale of opioids

Silver Spring, MD

Opioid addiction and abuse remains an immense public health crisis. We're committed to continuing to take new steps to address these protracted dangers from every possible angle.

Eli Lilly confirms date for second quarter of 2018 financial results announcement

Indianapolis

Eli Lilly and Company will announce its financial results for the second quarter of 2018 on Tuesday, July 24, 2018. Lilly will also conduct a conference call on that day with the investment community and media to

Novacyt to acquire Infectious Disease Business from Omega Diagnostics

Paris and Camberley

Novacyt, an international specialist in clinical diagnostics, announced that its protein diagnostics division, Lab21 Products (Lab21), has unconditionally entered into an asset purchase agreement to acquire the

GW Pharma receives US FDA approval for first plant-derived cannabidiol oral solution

London, UK, Carlsbad, CA

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary

Juniper Pharma Services continues its strategic capital investment in oral solid dose services

Nottingham, UK

Juniper Pharma Services (JPS), a Contract Development and Manufacturing Organisation (CDMO) specialising in the development of challenging small molecules, is continuing its strategic investment in oral

WuXi Biologics, Harbour BioMed collaborate to develop, manufacture Harbour's leading HCAb antibody

Shanghai and Cambridge

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Harbour BioMed

Eli Lilly completes acquisition of ARMO BioSciences

Indianapolis

Eli Lilly and Company recently announced the successful completion of its acquisition of ARMO BioSciences. Lilly's tender offer for all outstanding shares of common stock of ARMO, at a price of $50.00 per

Back

Enquiry Form